1. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT) 
Yago Nieto, MD, PhD, Roland Bassett, MS, Chitra Hosing, MD, Roy B. Jones, MD, PhD, Ben C. Valdez, PhD, Ashley Kingham, PA, Sairah Ahmed, MD, Amin M. Alousi, MD, Paolo Anderlini, MD, Uday R. Popat, MD, Muzaffar H. Qazilbash, MD, Elizabeth J. Shpall, MD, Partow Kebriaei, MD, Jonathan E. Brammer, MD, Yasuhiro Oki, MD, Michelle A. Fanale, MD, Farzaneh Maadani, BS, Gabriela Rondon, MD, Richard E. Champlin, MD, Borje S. Andersson, MD, PhD 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages S227-S228 (March 2016)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Outcomes of the R/R subgroups treated with Gem/Bu/Mel and BEAM. Fig. 1A: EFS. Fig 1B: OS
Biology of Blood and Marrow Transplantation  , S227-S228DOI: ( /j.bbmt )
Copyright © Terms and Conditions